Researchers from the Guangzhou Institutes of Biomedicine and Health have grown human-like kidneys in pigs.

Chinese scientists have succeeded in growing kidneys containing human cells in pig embryos, a world first that could one day help address organ donation shortages.

But the development, described in a study in the journal Cell Stem Cell on Thursday, raises ethical issues—especially since some human cells were also found in the pigs’ brains, experts said.

The researchers from the Guangzhou Institutes of Biomedicine and Health focused on kidneys because they are one of the first organs to develop, and the most commonly transplanted in human medicine.

“Rat organs have been produced in mice, and mouse organs have been produced in rats, but previous attempts to grow human organs in pigs have not succeeded,” senior author Liangxue Lai said in a statement.

“Our approach improves the integration of human cells into recipient tissues and allows us to grow human organs in pigs.”

This is a different approach to the recent high-profile breakthroughs in the United States, where genetically modified pig kidneys and even a heart have been placed inside humans.

The new paper “describes pioneering steps in a new approach to organ bioengineering using pigs as incubators for growing and cultivating human organs,” said Dusko Ilic, a professor of stem cell sciences at King’s College London who was not involved in the research.

Ilic cautioned there would be many challenges to turning the experiment into a viable solution, but “nevertheless, this captivating strategy warrants further exploration.”


Gene editing

A major challenge in creating such hybrids has been that pig cells outcompete human cells.

To overcome the obstacles, the team used CRISPR gene editing to delete two genes essential for kidneys to form inside a pig embryo, creating what’s called a “niche.”

They then added specially prepared human pluripotent stem cells—cells that have the potential to develop into any cell type—which filled the niche.

Before implanting the embryos in sows, they grew them in test tubes containing substances that nourished both the human and pig cells.

In total, they transferred 1,820 embryos into 13 surrogate mothers. The pregnancies were terminated at 25 and 28 days to assess how the experiment had worked.

Five embryos selected for analysis were found to have functionally normal kidneys for their stage of development, beginning to grow the ureters that would eventually connect them to the bladder.

They contained between 50 and 60 percent human cells.

“We found that if you create a niche in the pig embryo, then the human cells naturally go into these spaces,” said co-author Zhen Dai.

“We saw only very few human neural cells in the brain and spinal cord and no human cells in the genital ridge.”

Preventing the invasion of human cells into reproductive tissue is considered crucial, because otherwise there is a risk of uncontrolled creation of human-pig hybrids.

But the presence of any human cells in the pig brains still raises concerns, said Darius Widera, a professor of stem cell biology at the University of Reading.

“Although this approach is a clear milestone and the first successful attempt to grow whole organs containing human cells in pigs, the proportion of human cells in the generated kidneys is still not high enough,” he added.

In the long run, the team wants to optimize their technology for use in human transplantation, but admit it’s not ready yet.

An important limitation was the kidneys had pig-derived vascular cells, which could cause rejection if transplanted into a human.

Nevertheless, the scientists plan to press on and allow the kidneys to develop for a longer duration. They are also working on growing other human organs in pigs such as the heart and pancreas.

Check out our AAV CDMO service to expedite your gene therapy research
About PackGene

PackGene is a CRO & CDMO technology company that specializes in packaging recombinant adeno-associated virus (rAAV) vectors. Since its establishment in 2014, PackGene has been a leader in the AAV vector CRO service field, providing tens of thousands of custom batches of AAV samples to customers in over 20 countries. PackGene offers a one-stop CMC solution for the early development, pre-clinical development, clinical trials, and drug approval of rAAV vector drugs for cell and gene therapy (CGT) companies that is fast, cost-effective, high-quality, and scalable. Additionally, the company provides compliant services for the GMP-scale production of AAVs and plasmids for pharmaceutical companies, utilizing five technology platforms, including the π-Alpha™ 293 cell AAV high-yield platform and the π-Omega™ plasmid high-yield platform. PackGene’s mission is to make gene therapy affordable and accelerate the launch of innovative gene drugs. The company aims to simplify the challenging aspects of gene therapy development and industrialization processes and provide stable, efficient, and economical rAAV Fast Services to accelerate gene and cell therapy development efforts from discovery phase to commercialization.

Related News

Scientists develop potential stealth cancer therapy

Credit: ACS Central Science (2024). DOI: 10.1021/acscentsci.4c00559Sneaking by cancer's defenses, by disguising tumor-fighting antibodies inside the molecules cancer uses to nourish tumor growth, is the basis of a novel therapy from Yale Cancer Center researchers at...

read more

Related Services

Plasmids GMP Services

Multiple scales & grade of solutions of various kind of plasmids suitable for multiple treatments in a fast and cost effective way.


AAV GMP Services

Ranging from small-scale AAV production, to large-scale AAV cGMP manufacturing for animal studies.


aav icon

Technology Platforms

PackGene’s proprietary π-Alpha™ 293 AAV High-yield Platform increases AAV production by 3 to 8 times that of traditional platforms.